On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
BUSINESS
Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
Oncolys BioPharma’s oncolytic virus therapy Telomelysin (suratadenoturev) made its debut in Japan on August 21, with Fujifilm Toyama Chemical handling sales and promotional activities. Under a sales partnership with developer Oncolys, Fujifilm Toyama Chemical is responsible for sales, distribution, and…
To read the full story
Related Article
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Oncolys Targets 300 Hospitals for Telomelysin Rollout
June 9, 2026
- Japan Approves Oncolys’ Telomelysin for Esophageal Cancer
June 8, 2026
- Oncolys’ Telomelysin Wins Backing from Japan Panel
May 22, 2026
- Oncolys’ Telomelysin Up for Japan Panel Review on May 21
May 15, 2026
- Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Oncolys’ Oncolytic Virus Telomelysin Gets Orphan Status in Japan
December 15, 2025
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
- Oncolys Forms Oncolytic Virus Sales Collab with Fujifilm in Japan
February 8, 2024
- Telomelysin-Radiation Combo Hits Mark in PII Esophageal Cancer Study: Oncolys
October 17, 2023
- Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
December 20, 2022
- 2024 Japan Filing Plan for Oncolytic Virus Unchanged: Oncolys President
August 8, 2022
- PI Telomelysin Trial for Esophageal Cancer Begins in US: Oncolys
December 8, 2021
- Chugai, Oncolys to Call Off License Deal for Telomelysin
October 20, 2021
- Telomelysin Submission Likely Delayed into 2024 or Later: Oncolys/Chugai
April 15, 2021
- Telomelysin-Keytruda Combo Trial to Begin in US for Head and Neck Cancer: Oncolys
August 11, 2020
- Investigator-Initiated Study to Be Launched for Telomelysin/Radiotherapy in US: Oncolys
June 11, 2020
- 1st Patient Dosed Telomelysin Together with Radiotherapy in Japan PII Study for Esophageal Cancer: Chugai
March 5, 2020
- Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
- US PII Study for Telomelysin-Keytruda Combo Begins for Esophageal Cancer
May 14, 2019
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
- Investigator-Initiated US PII Study to Start for Telomelysin/Keytruda Combo: Oncolys
January 9, 2019
BUSINESS
- Keytruda Holds Japan Sales Crown in July-September as Mounjaro Climbs: IQVIA
November 13, 2026
- Genmab Eyes Early Japan Launches for 2 Cancer Blockbuster Hopefuls
November 13, 2026
- FRONTEO, Human Life CORD Tap AI to Unravel Cell Therapy Mechanisms
November 13, 2026
- Toho Unit Finds No Evidence of Data Leak after Email Service Breach
November 13, 2026
- Daiichi Sankyo Files Enhertu for Uterine Carcinosarcoma in Japan
November 13, 2026
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…